alexa Scholarly Open Access Journals In Molecular Signatures|OMICS International|Journal Of Molecular Biomarkers And Diagnosis

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Scholarly Open Access Journals In Molecular Signatures

Scholarly open access journals have emerged as an alternative to traditional subscription journals. Open access scholarly journals are available online to the reader without financial, legal, or technical barriers. Scholarly open access journals are journals which are respected for the extensive research and information they provide about the point. The research often possesses refereed meaning that it is reviewed by other scientists who are knowledgeable about the theme of the article. Scholarly open access journals cite their sources using references or bibliographies. OMICS Group International has 700+ peer-reviewed journals and organizes 3000+ International Scientific Conferences worldwide. Apart from providing a free access to articles to everyone, it also extends support to other scholarly journals in the peer-review process, production, and distribution. All the articles published in OMICS Group journals are peer reviewed and published only on adhering to the norms. Upon acceptance, the articles will be immediately and permanently free for everyone to read and download. OMICS Group International has established agreements with 1000+ Scientific associations by covering some or all of the publication costs for their individual researchers. Tumor recurrence and metastases are the major obstacles to improve the prognosis of patients with hepatocellular carcinoma (HCC).the identification of blood-based diagnostic and prognostic biomarkers that surpass existing clinicopathologic factors in gauging the risk of early recurrent disease in patients with HCC and the development of HCC in high-risk CHB patients.To identify novel molecular signatures associated with HCC recurrence and metastases, we have established an expression database of HCC patients using Affymetrix gene chips. Samples from patients with early recurrent disease were compared with non-recurrent human HCC tissue samples (recurrence is defined as recurrent disease occurring within a 2-year time point of the original treatment). Novel biomarkers associated with early HCC recurrence have been characterized and are being employed as diagnostic markers for early recurrent disease.Metastasis that is responsible for the majority of cancer-related deaths is initiated by cancer cells that are shed and disseminated through the circulation from the primary tumor to distant organs (circulating tumor cells, CTCs). Although the detection of CTCs may have important prognostic and therapeutic implications, their detection poses key technical challenges because their numbers can be very small. Great efforts have therefore been made toward the enhancement of signal amplification to significantly increase the sensitivity for the detection of tumor-specific biomarkers on the surface of CTCs.High sensitivity is achieved by using graphene to modify the immunosensor surface to accelerate electron transfer and quantum dot (QD)-coated silica nanoparticles as tracing tags. On the other hand, high specificity is obtained by the simultaneous measurement of multiple HCC-specific biomarkers, identified through the microarray studies, on the cell surface of CTCs using different QD-coated silica nanoparticle tracers. (Kam Man Hui, Identification of blood-based molecular signatures to detect early human hepatocellular carcinoma)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014

Top